2025-11-17T11:45:23-06:00 2024-12-31 263753134 CBIZ ADVISORS LLC 53 STATE STREET 17TH FLOOR BOSTON MA 02109 990 2024-01-01 461681862 OPENBIOME FOUNDATION INC OPEN 6175752201 PO BOX 3089 WESTPORT MA 02790 JULIE BARRETT O'BRIEN CHIEF EXECUTIVE OFFICER 6175752201 2025-11-17 1 1 BRENDA L BOOTH P01342395 6178075000 2025-11-17 2024 2025-03-06 01:10:19Z X X JULIE BARRETT O'BRIEN PO BOX 3089 WESTPORT MA 02790 5546214 0 X WWW.OPENBIOME.ORG X 2013 MA OPENBIOME'S MISSION IS TO EXPAND PATIENT ACCESS TO MICROBIOME THERAPIES AND FUEL SCIENTIFIC DISCOVERIES THAT SHAPE THE FUTURE OF HEALTH. 9 9 26 9 0 0 785396 118937 22100 0 309412 295943 3259140 1774007 4376048 2188887 0 201212 0 0 2320669 2267068 0 0 0 1189107 896329 3509776 3364609 866272 -1175722 9964560 8894988 1232036 1301982 8732524 7593006 X SEE SCHEDULE O 0 1 2360760 1712357 OPENBIOME REMAINED COMMITTED TO ENSURING THAT ALL PATIENTS SUFFERING FROM C. DIFFICILE INFECTION CONTINUED TO HAVE SAFE, CONVENIENT, AND AFFORDABLE ACCESS TO FECAL MICROBIOTA TRANSPLANTATION (FMT) THROUGH THEIR PHYSICIAN. IN OUR COLLABORATION WITH THE UNIVERSITY OF MINNESOTA (UMN), UNDER AN ACTIVE INVESTIGATIONAL NEW DRUG (IND), WE CONTINUED TO DISTRIBUTE FMT TO OUR CLINICAL NETWORK. HOWEVER, IN MID-YEAR, REGULATORY CHANGES NECESSITATED THAT WE CEASE PROVIDING THESE TREATMENTS. AFTER 12 YEARS AND OVER 72,000 TREATMENTS, WE HAD NO CHOICE BUT TO DISCONTINUE THIS PROGRAM. 49407 CLINICAL RESEARCH PROGRAM: OPENBIOME SEEKS TO ENABLE TRANSLATIONAL RESEARCH ON THE HUMAN MICROBIOME. TO ACHIEVE THIS, WE OFFER A SUITE OF SERVICES DESIGNED TO HELP INVESTIGATORS UNCOVER THE ROLE OF THE GUT MICROBIOME IN HUMAN HEALTH AND EXPLORE HOW ENGINEERING IT CAN LEAD TO IMPROVED HEALTH OUTCOMES. OUR SERVICES INCLUDE STUDY DESIGN AND REGULATORY SUPPORT FOR CLINICAL TRIALS, AND BIOINFORMATICS AND ANALYTICAL SERVICES. OPENBIOME ALSO SPONSORS ITS OWN STUDIES INVESTIGATING CRITICAL MICROBIOME-RELATED HEALTH CONDITIONS. 299986 201212 THE GLOBAL MICROBIOME CONSERVANCY (GMBC) PARTNERS WITH SCIENTISTS WORLDWIDE TO CONSERVE, STUDY, AND SHARE THE UNDERREPRESENTED AND AT-RISK DIVERSITY OF HUMAN MICROBIOMES. THE GMBC HAS ESTABLISHED A NETWORK OF 80+ RESEARCHERS IN OVER THREE DOZEN COUNTRIES AND BUILT A DIVERSE COLLECTION OF SAMPLES AND BACTERIAL ISOLATES TO SPARK SCIENTIFIC DISCOVERY AND ENABLE NEW SOLUTIONS TO MICROBIOME-ASSOCIATED DISEASE. IN 2024, OPENBIOME SUPPORTED THIS PROGRAM BY PROVIDING GRANTS TO AID IN THE COLLECTION OF SAMPLES AND ISOLATES IN VARIOUS COUNTRIES. 2710153 1 1 0 0 0 0 0 0 0 0 1 1 0 1 1 1 1 0 0 1 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 23 0 1 26 1 0 0 0 0 0 0 0 0 0 0 0 0 X 9 9 0 0 1 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MA X X PAUL LEECH 6175752201 PO BOX 3089 WESTPORT MA 02790 LISA SERWIN DIRECTOR/VICE CHAIR & SECRETARY 2.00 X X 0 0 0 JANE WILLIAMS MD DIRECTOR/TREASURER 2.00 X X 0 0 0 NEIL RASMUSSEN DIRECTOR/BOARD CHAIR 2.00 X X 0 0 0 ERIC ALM PHD DIRECTOR 2.00 X 0 0 0 JAMES BILDNER DIRECTOR 2.00 X 0 0 0 STEPHEN JONES DIRECTOR 2.00 X 0 0 0 JOANNE KAMENS PHD DIRECTOR 2.00 X 0 0 0 RUCHIKA KUMAR DIRECTOR 2.00 X 0 0 0 GARABET YERETSSIAN PHD DIRECTOR 2.00 X 0 0 0 JULIE O'BRIEN CHIEF EXECUTIVE OFFICER 40.00 X 238319 0 40452 PAUL LEECH CHIEF ADMINISTRATIVE OFFICER 25.00 X 143090 0 6004 MAJDI OSMAN MD MPH CHIEF MEDICAL OFFICER 40.00 X 89318 0 3171 KEN LINDE CHIEF OPERATING OFFICER 40.00 X 214271 0 39572 SHEVON WALKER DIR. OF CMC & SUPPLY CHAIN LOGISTICS 40.00 X 170988 0 37538 DAVE MCCALL HUMAN RESOURCES DIRECTOR 40.00 X 150203 0 37713 DANA SHAMITZ QUALITY SUPERVISOR 40.00 X 139074 0 23998 MICHAEL BOUGAS DIRECTOR OF OUTREACH 40.00 X 138468 0 26254 CYLEIGH MERTZ CHIEF OF STAFF 40.00 X 126193 0 22828 1409924 0 237530 10 0 1 0 MINTZ LEVIN COHN 1 FINANCIAL CENTER FLOOR 39 BOSTON MA 02111 LEGAL 158096 1 64550 54387 118937 325422 325422 8000 25366 12113 -25366 -4113 -29479 -29479 5032205 3319848 1712357 1712357 OTHER INCOME 900099 61650 61650 61650 2188887 1712357 0 357593 201212 201212 697473 534961 162512 1093441 923236 170205 48727 39765 8962 302044 231668 70376 125383 102743 22640 226994 174636 52358 60000 46020 13980 14925 14925 153082 117414 35668 224007 171813 52194 26348 20209 6139 37944 29103 8841 30030 23033 6997 122999 94340 28659 3364609 2710153 654456 0 2003562 1619939 87947 70261 406334 406334 779575 244223 155400 0 99988 57324 450072 384522 107693 65550 203377 200746 5360434 5658517 760250 572094 9964560 8894988 530567 819273 701469 482709 1232036 1301982 X 8732524 7593006 8732524 7593006 9964560 8894988 -1175722 36204 0 X 0 1 X 1 0 X 377967 1212784 926050 785396 118937 3421134 9646475 7423251 6500830 7339929 5032205 35942690 10024442 8636035 7426880 8125325 5151142 39363824 244000 27560 11919 14029 52193 349701 0 244000 27560 11919 14029 52193 349701 39014123 259796 1348357 161762 233309 325422 2328646 259796 1348357 161762 233309 325422 2328646 10284238 9984392 7588642 8358634 5476564 41692470 0.93580 0.94530 0.05590 0.04320 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 294703 272838 21865 82107 38422 43685 73262 73262 0 65550 CORPORATE BONDS 4711229 F U.S. TREASURIES 801867 F GOVERNMENT BONDS 145421 F 5658517 SECURITY DEPOSIT 167400 RIGHT-OF-USE ASSETS, OPERATING LEASE 404694 572094 OPERATING LEASE OBLIGATION 404694 PAYCHECK PROTECTION PROGRAM LOAN 78015 482709 X 2008954 36204 -201212 -165008 2173962 14925 14925 2188887 3148472 0 3148472 14925 201212 216137 3364609 PART X, LINE 2: THE ORGANIZATION ACCOUNTS FOR THE EFFECT OF ANY UNCERTAIN TAX POSITIONS BASED ON A "MORE LIKELY THAN NOT" THRESHOLD TO THE RECOGNITION OF THE TAX POSITIONS BEING SUSTAINED BASED ON THE TECHNICAL MERITS OF THE POSITION UNDER SCRUTINY BY THE APPLICABLE TAXING AUTHORITY. IF A TAX POSITION OR POSITIONS ARE DEEMED TO RESULT IN UNCERTAINTIES OF THOSE POSITIONS, THE UNRECOGNIZED TAX BENEFIT IS ESTIMATED BASED ON A "CUMULATIVE PROBABILITY ASSESSMENT" THAT AGGREGATES THE ESTIMATED TAX LIABILITY FOR ALL UNCERTAIN TAX POSITIONS. INTEREST AND PENALTIES ASSESSED, IF ANY, ARE ACCRUED AS INCOME TAX EXPENSE. THE ORGANIZATION HAS IDENTIFIED ITS STATUS AS A TAX EXEMPT ENTITY AS ITS ONLY SIGNIFICANT TAX POSITION AND HAS DETERMINED THAT SUCH TAX POSITION DOES NOT RESULT IN AN UNCERTAINTY REQUIRING RECOGNITION. THE ORGANIZATION IS NOT CURRENTLY UNDER EXAMINATION BY ANY TAXING JURISDICTION. 1 EUROPE (INCLUDING ICELAND & GREENLAND) 0 1 PROGRAM SERVICES MALNUTRITION RESEARCH, UN SCIENCE SUMMIT PARTICIPATION, AND TRANPORT OF BIOLOGICAL SAMPLING. 146065 MIDDLE EAST AND NORTH AFRICA 0 0 GRANTING 26658 SOUTH AMERICA 0 0 GRANTING 47389 EAST ASIA AND THE PACIFIC 0 0 GRANTING 4936 RUSSIA AND NEIGHBORING STATES 0 0 GRANTING 5000 0 1 0 0 0 1 230048 0 230048 MIDDLE EAST AND NORTH AFRICA BIOLOGICAL SAMPLING 26658 0 SOUTH AMERICA BIOLOGICAL SAMPLING 47389 0 0 2 0 0 0 0 0 0 PART I, LINE 2: REPORTS ARE REQUIRED TO SHOW PROGRESS AGAINST MILESTONES (IMPACT) AND ACTUAL VERSUS BUDGETED SPEND. PHOTOGRAPHS AND VIDEOS, WHERE RELEVANT, ARE ENCOURAGED BUT NOT MANDATED. FOR ALL GRANTS, A FINAL REPORT IS REQUIRED ON COMPLETION. FOR PROJECTS LASTING MORE THAN SIX MONTHS, AN INTERIM REPORT IS REQUIRED AT THAT POINT. X X 1 0 0 0 0 0 0 1 0 JULIE O'BRIEN CHIEF EXECUTIVE OFFICER 205778 0 31828 0 713 0 7313 0 33139 0 278771 0 0 0 KEN LINDE CHIEF OPERATING OFFICER 186596 0 27675 0 0 0 6592 0 32980 0 253843 0 0 0 SHEVON WALKER DIR. OF CMC & SUPPLY CHAIN LOGISTICS 125072 0 18672 0 27244 0 4492 0 33046 0 208526 0 0 0 DAVE MCCALL HUMAN RESOURCES DIRECTOR 130270 0 19492 0 441 0 4673 0 33040 0 187916 0 0 0 MICHAEL BOUGAS DIRECTOR OF OUTREACH 119710 0 18346 0 412 0 4216 0 22038 0 164722 0 0 0 DANA SHAMITZ QUALITY SUPERVISOR 103602 0 15129 0 20343 0 3630 0 20368 0 163072 0 0 0 PART I, LINE 3 MEMBERS OF THE BOARD OF DIRECTORS MUST APPROVE OFFICER COMPENSATION. THIS COMPENSATION IS REVIEWED ANNUALLY AGAINST INDUSTRY AND MARKET COMPARABLES. COMPENSATION IS SET BY INDEPENDENT PERSONS AND DOCUMENTED CONTEMPORANEOUSLY. PART I, LINE 4A SHEVON WALKER RECEIVED A SEVERANCE PAYMENT IN THE AMOUNT OF $26,776 DURING 2024. DANA SHAMITZ RECEIVED A SEVERANCE PAYMENT IN THE AMOUNT OF $20,343 DURING 2024. PART I, LINE 7 THE BOARD REVIEWS THE FINANCIALS AND HAS THE OPTION EACH YEAR TO DECLARE SOME OR NO BONUSES. IF THE BOARD DECIDES TO GIVE A BONUS, AN OVERALL PERCENTAGE IS RECOMMENDED. A STAFF LIST IS THEN DEVELOPED BASED ON THE RECOMMENDATION AND REVIEWED BY TOP LEADERSHIP, WHERE PERFORMANCE BASED ADJUSTMENTS MAY BE MADE. FORM 990, PART III, LINE 1, DESCRIPTION OF ORGANIZATION MISSION: OPENBIOME BELIEVES IN A WORLD WHERE MICROBIOME SCIENCE REVOLUTIONIZES HEALTH, MAKING LIFE-SAVING THERAPIES ACCESSIBLE TO ALL. OUR MISSION IS TO EXPAND PATIENT ACCESS TO MICROBIOME THERAPIES AND FUEL SCIENTIFIC DISCOVERIES THAT SHAPE THE FUTURE OF HEALTH. WE BUILD PARTNERSHIPS, FUND INNOVATION, AND SHARE OPEN-ACCESS TOOLSSO THAT THE IMPACT OF MICROBIOME SCIENCE LIVES ON, LONG AFTER OUR MISSION IS COMPLETE. WE EXIST TO ACCELERATE THAT PROGRESSBY HELPING DELIVER TODAY'S MOST PROMISING TREATMENTS, WHILE LAYING THE GROUNDWORK FOR TOMORROW'S BREAKTHROUGHS. WE WILL CONTINUE TO CHAMPION ACCESS TO FMT FOR C. DIFF PATIENTS, STARTING WITH ADVOCACY FOR SOUND HEALTH POLICY AND NEW MODELS FOR HOSPITAL-BASED FMT PROGRAMS. WE WILL SUPPORT PIONEERING RESEARCH THROUGH TARGETED GRANTMAKING AND GLOBAL COLLABORATIONS. WE WILL BUILD FOR THE FUTURE BY OPENLY SHARING OUR EXPERTISE AND UNPARALLELED BIOREPOSITORY TO POWER THE NEXT GENERATION OF DISCOVERIES. FORM 990, PART III, LINE 3 IN LATE 2024, DUE TO REGULATORY CHANGES, WE WERE FORCED TO DISCONTINUE OUR FMT PROGRAM. OUR FOCUS AND STRATEGY SHIFTED, AND WE INITIATED THE PROCESS OF ESTABLISHING THE OPENBIOME FOUNDATION. THIS FOUNDATION WAS ESTABLISHED IN EARLY 2025 AND WILL CONTINUE TO SUPPORT THE DELIVERY OF GROUND-BREAKING MICROBIOME-TARGETED THERAPIES TO CHANGE OUTCOMES FOR PEOPLE FACING SERIOUS, OFTEN LIFE-THREATENING CONDITIONS. FORM 990, PART VI, SECTION A, LINE 4 THE ORGANIZATION CHANGED ITS NAME TO OPENBIOME FOUNDATION INC. FORM 990, PART VI, SECTION B, LINE 11B COPIES OF THE COMPLETED DRAFT FORM 990 (INCLUDING REQUIRED SCHEDULES) WILL BE DISTRIBUTED TO THE AUDIT COMMITTEE MEMBERS BY EITHER ELECTRONIC OR PAPER FORM FOR REVIEW AND APPROVAL. ANY QUESTIONS OR CONCERNS WILL BE NOTED AND ADDRESSED, AND MANAGEMENT STAFF WILL ENSURE THAT CHANGE ARE INCORPORATED INTO THE FORM 990 AS APPROPRIATE. AFTER ALL INPUT HAS BEEN APPROPRIATELY ADDRESSED, THE FINAL VERSION OF THE FORM 990 (WITH REQUIRED SCHEDULES) WILL BE DISTRIBUTED TO EVERY VOTING MEMBER OF THE ORGANIZATION'S BOARD OF DIRECTORS PRIOR TO FILING WITH THE IRS. THE FINAL FORM MAY BE DISTRIBUTED EITHER IN PAPER OR ELECTRONIC FORM IN ANY MANNER DEEMED APPROPRIATE BY THE ORGANIZATION'S CHIEF OPERATING OFFICER. FORM 990, PART VI, SECTION B, LINE 12C ALL STAFF, OFFICERS, AND DIRECTORS ARE REQUIRED TO SIGN THE CONFLICT OF INTEREST POLICY AND DISCLOSE ANY POTENTIAL OR PERCEIVED CONFLICTS TO MANAGEMENT. ANY CONFLICTS OF INTEREST DISCLOSED ARE DISCUSSED BY THE BOARD OF DIRECTORS AND MANAGEMENT. FORM 990, PART VI, SECTION B, LINE 15 MEMBERS OF THE BOARD OF DIRECTORS MUST APPROVE OFFICER COMPENSATION. THIS COMPENSATION IS REVIEWED ANNUALLY AGAINST INDUSTRY AND MARKET COMPARABLES. COMPENSATION IS SET BY INDEPENDENT PERSONS AND DOCUMENTED CONTEMPORANEOUSLY. FORM 990, PART VI, SECTION C, LINE 19 FORMS 990 AND ANNUAL AUDITED FINANCIAL STATEMENTS ARE POSTED ON THE COMPANY WEBSITE, WWW.OPENBIOME.ORG, AS WELL AS GUIDESTAR.ORG.